Discounted Cash Flow
Connect Biopharma Holdings Ltd. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2012 | $0 | $-1.0m | $-1.0m | — | $-0.11 |
| 2013 | $0 | $-18.9k (98.1%) | $-209 (100.0%) | — | $0.01 (109.1%) |
| 2014 | $0 | $227.8k (1304.8%) | $237.4k (113670.8%) | — | $0.01 (0.0%) |
| 2019 | — | $-168.6m (-74110.9%) | $-91.3m (-38576.1%) | — | — |
| 2020 | — | $-779.2m (-362.1%) | $-182.1m (-99.4%) | — | $-45.60 |
| 2021 | $398.4k | $-205.0m (73.7%) | $-545.5m (-199.5%) | -51449.9% | $-25.00 (45.2%) |
| 2022 | $7.0m (1644.6%) | $-114.4m (44.2%) | $-709.0m (-30.0%) | -1646.6% (96.8%) | $-14.50 (42.0%) |
| 2023 | $1.4m (-79.9%) | $-59.5m (48.0%) | $-47.9m (93.2%) | -4255.9% (-158.5%) | $-1.08 (92.6%) |
| 2024 | $26.0m (1762.0%) | $-15.6m (73.7%) | $-24.4m (49.2%) | -60.0% (98.6%) | $-0.28 (74.1%) |
| 2025 | $2.3m (-91.3%) | $-55.5m (-255.0%) | $-51.6m (-112.0%) | -2446.2% (-3974.9%) | $-1.00 (-257.1%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.